Cue Biopharma, Inc. filings document material events, governance actions, operating results, and capital-structure matters for a clinical-stage biopharmaceutical company focused on immune-modulating biologics. The company's 8-K reports cover executive transitions, collaboration milestones, financial results, registered common stock matters, and amendments related to a reverse stock split.
Proxy and meeting-related filings describe director elections, auditor ratification, executive compensation votes, stockholder proposal procedures, and amendments to governing documents. Other disclosures address research and development programs including CUE-401, CUE-501, the Immuno-STAT platform, collaboration and license agreements, equity compensation arrangements, and risk factors associated with clinical-stage biotechnology operations.
Cue Biopharma, Inc. appointed James Ahlers as Chief Financial Officer and principal financial officer, effective July 30, 2026, under an executive employment agreement. Ahlers, age 62, brings extensive biotech finance experience, including prior roles at Intarcia Therapeutics, RenovoRx, Titan Pharmaceuticals and other life sciences companies.
The agreement provides a $450,000 annual base salary and an annual incentive bonus targeted at up to 45% of base salary. On the effective date, he received inducement equity grants under the 2026 Inducement Stock Incentive Plan: nonstatutory stock options to purchase 51,00 shares at an exercise price of $30.40 per share and a restricted stock unit award for 25,500 shares, vesting quarterly over four years. Upon certain qualifying terminations, including in connection with a change in control, he is eligible for cash severance, continued COBRA premium payments for up to nine months, and accelerated vesting of equity awards, subject to customary release and other conditions.
Cue Biopharma, Inc. granted Chief Financial Officer James M. Ahlers two equity awards on July 30, 2026: a stock option for 51,000 shares of common stock at an exercise price of $30.40 per share, expiring July 30, 2036, and 25,500 restricted stock units. Both the option and RSUs vest in equal quarterly installments over four years from July 30, 2026, subject to his continued service with the company through each vesting date.
Cue Biopharma, Inc. reports that its Chief Financial Officer, James M. Ahlers, has become a reporting insider under SEC rules through an initial statement of beneficial ownership. The filing lists no equity transactions and no reportable holdings for Ahlers at the time of this report.
Cue Biopharma Chief Executive Officer Shao-Lee Lin, through the Shao-Lee Lin Trust dated March 13, 2023, reported acquiring 90,906 pre-funded warrants and 45,453 common stock warrants on June 1, 2026. These securities were issued in a private placement under an April 30, 2026 securities purchase agreement at $11.00 per pre-funded warrant plus accompanying half-share warrant. The pre-funded warrants have a $0.001 exercise price and no expiration; the common stock warrants have an $11.00 exercise price and expire on May 4, 2031. Both series became exercisable on June 1, 2026 after stockholder approval, and the board approved the transactions under Rule 16b-3. The amendment corrects only the previously reported transaction code.
Cue Biopharma, Inc., a Delaware biotechnology company based in Boston, filed a notice of an exempt private securities offering. The company is relying on Regulation D, Rule 506(b) and has conducted a new offering of equity, warrants or other rights to acquire securities, and the securities issuable upon exercise of those rights.
The offering shows a total amount sold of $49,999,927 with $0 remaining to be sold, indicating the round is fully subscribed as reported here. The date of first sale is listed as July 13, 2026. No finders’ fees are reported, with finders’ fees stated as $0. The issuer declined to disclose its revenue range.
Cue Biopharma, Inc. granted its Chief Medical Officer and Head of Research & Development, Dominique Christian Borie, 31,500 restricted stock units (RSUs) and stock options for 63,000 shares of common stock. The options carry an exercise price of $30.9200 per share and expire on July 13, 2036.
The RSUs and options each vest in equal quarterly installments over four years starting July 13, 2026, contingent on Borie’s continued service with the company. Following these grants, Borie holds 31,500 common shares and options on 63,000 shares directly.
Cue Biopharma, Inc. reports Dominique Christian Borie, its Chief Medical Officer and Head of Research & Development, as a reporting person on a Form 3 (initial statement of beneficial ownership of securities). The Form 3 data shows no reported share transactions or derivative exercises by Borie.
Garzone Pamela reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. reported that director Pamela Garzone received a grant of 21,800 shares of Common Stock in the form of restricted stock units. One-third of the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, contingent on her continued service with the company. Following this equity award, she holds 21,800 shares directly.
Camardo Daniel A. reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. reported that director Daniel A. Camardo received a grant of 21,800 shares of Common Stock in the form of restricted stock units. One-third of these RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to his continued service with the company. Following this award, he holds 21,800 shares of Common Stock directly.
Sarraf Pasha reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. director Sarraf Pasha received a grant of 21,800 restricted stock units (RSUs) of common stock. One-third of these RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to continued service. Following this award, Pasha holds 32,595 shares (on a post–1-for-30 reverse split basis effective April 22, 2026).